Coeptis Therapeutics Hldgs Inc (COEP) Stock Price, Quote & News

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology

Sector: Healthcare

Phone: 724 934 6467

Website: coeptistx.com

Address:

105 Bradford Road, Suite 420, Wexford, United States

Stock_Catcher Aug. 18 at 2:04 AM

Money Monday Watchlist Pt. 11 $COEP $ENPH $CUPR $OVID $GALT Let's Have an Amazing Week 💵

0 · Reply

jschor88 Aug. 17 at 11:40 PM

$COEP 🚀🚀🔥🔥💥💥

0 · Reply

futuregssummeranalyst Aug. 17 at 1:52 PM

$COEP @AViniS notice how your posts gain zero traction

1 · Reply

AViniS Aug. 17 at 1:48 AM

$COEP Just stop to think. I biotech firm that were doing preclinical work on cancer therapies, is now switching to become a Dog "Shit" Coin Miner. 🤦‍♂️What are these markets coming to. Apparently they are waiting to file preliminary and then definitive proxy, meaning that shareholders still need to vote for this, no date set. This is going to take months. The more I look into this, the more I question what in the world is going on here. They are still also waiting for another audit review of their 1990's machinery to mine Shit Coins, and in the mean time the insiders just filed to sell 20 million shares!!! Good luck.

0 · Reply

WallStreetBuyDip Aug. 16 at 11:57 PM

got $COEP on radar but need H% to get low first like usual

0 · Reply

GrindTime Aug. 16 at 10:16 PM

$COEP 12.47?

0 · Reply

futuregssummeranalyst Aug. 16 at 9:54 PM

$COEP someone missed the train

1 · Reply

makedatbread88 Aug. 16 at 9:53 PM

Hope everyone has a good weekend. The rest of August into September is going to be massive folks. Mark this post I see all of these tickers having big moves from current prices. If you’re not in any of these it’s not too late to add come Monday. Amazing time to be in these tickers below going to be massive👇 $COEP $TLRY $NEOV $NLSP $TRNR

5 · Reply

AViniS Aug. 16 at 8:35 PM

$COEP Garbage in, Garbage out! Coeptis and Z Square are both a shambles. Have any of you seen Z Square's mining network. The machines are so old, they were probably made in the 90's. They are fudging the numbers to make believe a valuation that won't hold up once it is properly audited. Don't trust this merger deal at all. If Coeptis merger was such a "great" deal, why are insiders filing to resell almost 20 million in shares and warrants. This is just 1 insider, there are 3 in total selling all of their stock! Good luck with this garbage, they are using you to drive up the stock price.

0 · Reply

futuregssummeranalyst Aug. 16 at 8:14 PM

$COEP why cant the market be open rn

0 · Reply

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jun 26, 2025, 8:34 AM EDT - 7 weeks ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

May 28, 2025, 8:28 AM EDT - 2 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Apr 25, 2025, 8:33 AM EDT - 4 months ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 17, 2025, 8:38 AM EDT - 4 months ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Mar 11, 2025, 8:34 AM EDT - 5 months ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 7, 2025, 8:37 AM EST - 5 months ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 5 months ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

Feb 20, 2025, 9:00 AM EST - 6 months ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 7:27 AM EST - 6 months ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 13, 2025, 8:39 AM EST - 6 months ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 6, 2025, 8:08 AM EST - 6 months ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Jan 30, 2025, 8:27 AM EST - 7 months ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 23, 2025, 8:09 AM EST - 7 months ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 22, 2025, 8:00 AM EST - 7 months ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 7, 2025, 8:00 AM EST - 7 months ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Dec 27, 2024, 8:15 AM EST - 8 months ago

Coeptis Therapeutics Announces Reverse Stock Split

Dec 26, 2024, 8:15 AM EST - 8 months ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 8 months ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 3, 2024, 8:15 AM EST - 9 months ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Nov 7, 2024, 8:07 AM EST - 10 months ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Oct 24, 2024, 8:07 AM EDT - 10 months ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 15, 2024, 8:07 AM EDT - 10 months ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Sep 19, 2024, 7:07 AM EDT - 11 months ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

May 30, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 8, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Feb 26, 2024, 9:00 AM EST - 1 year ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 7, 2024, 7:30 AM EST - 1 year ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Jan 4, 2024, 7:30 AM EST - 1 year ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Dec 4, 2023, 7:30 AM EST - 1 year ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Oct 31, 2023, 9:01 AM EDT - 1 year ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 24, 2023, 8:30 AM EDT - 1 year ago

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 9, 2023, 9:15 AM EDT - 2 years ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

$Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection$

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Aug 30, 2023, 1:00 PM EDT - 2 years ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 17, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Jun 16, 2023, 4:00 PM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Jun 14, 2023, 9:28 AM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Jun 9, 2023, 7:00 AM EDT - 2 years ago

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

May 17, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

Stock_Catcher Aug. 18 at 2:04 AM

Money Monday Watchlist Pt. 11 $COEP $ENPH $CUPR $OVID $GALT Let's Have an Amazing Week 💵

0 · Reply

jschor88 Aug. 17 at 11:40 PM

$COEP 🚀🚀🔥🔥💥💥

0 · Reply

futuregssummeranalyst Aug. 17 at 1:52 PM

$COEP @AViniS notice how your posts gain zero traction

1 · Reply

AViniS Aug. 17 at 1:48 AM

0 · Reply

WallStreetBuyDip Aug. 16 at 11:57 PM

got $COEP on radar but need H% to get low first like usual

0 · Reply

GrindTime Aug. 16 at 10:16 PM

$COEP 12.47?

0 · Reply

futuregssummeranalyst Aug. 16 at 9:54 PM

$COEP someone missed the train

1 · Reply

makedatbread88 Aug. 16 at 9:53 PM

5 · Reply

AViniS Aug. 16 at 8:35 PM

0 · Reply

futuregssummeranalyst Aug. 16 at 8:14 PM

$COEP why cant the market be open rn

0 · Reply

BullMrketsBack Aug. 16 at 8:03 PM

🚨TGL🚨 --->Treasure Global, On High Squeeze Watch! This low float (2.7M) Crypto stock setting up to be the next 200%+ runner as BTC/ETH at all time highs. -Multiple catalyst upcoming. trading well under book value here and a crypto treasury play with BTC and ETH $CASI $TNYA $COEP $HCTI

0 · Reply

StockScanners Aug. 16 at 3:36 AM

$COEP keep watch if this holds above 12.40

0 · Reply

futuregssummeranalyst Aug. 15 at 8:35 PM

$COEP honestly insane day. Lets keep it going to $20. Not selling until then. And will be holding half for $25

0 · Reply

Jeko44 Aug. 15 at 8:03 PM

$COEP so much spam…must be getting noticed

0 · Reply

dalrosalez Aug. 15 at 7:51 PM

$COEP This float is lighter than BTC maxis’ bags — PT $0.55 🚀💎

2 · Reply

topstockalerts Aug. 15 at 7:36 PM

$COEP Looking good!.....

0 · Reply

kevinFlint Aug. 15 at 7:30 PM

Fintel is showing 383 total institutions holding $ROOT, a change of 1.81mm shares or a 20.35% increase. this number likely does not include NP filings and/or other insider holdings where over 3M shares are held by funds. Nonetheless the float is getting tighter and tighter $DJT $ENPH $COEP $RUN

2 · Reply

Duskfall Aug. 15 at 7:28 PM

$COEP You should follow them! @MKRReformed @The1Albatross 👈 They know this stuff👇

0 · Reply

makedatbread88 Aug. 15 at 7:20 PM

$COEP nobody liked it back in January when it first reverse split now watch everyone chase it 🚀🚀🐎🐎🤷‍♂️🤷‍♂️🤷‍♂️ long journey here congrats to those who bought to start off the year this is the first inning! $20+ then $30+ next 🚀🚀🚀 ****Follow me for more winning calls!****

0 · Reply

makedatbread88 Aug. 15 at 7:18 PM

$COEP trending!!!!! Who bought? Who listened to my call just 4 hours ago? Let’s go!!!!!! ***Follow me for more winning calls!***

0 · Reply

Rounderssss4 Aug. 15 at 7:15 PM

$COEP shit is about to get real here

0 · Reply

kevinFlint Aug. 15 at 7:10 PM

Breaking: Institutions are buying $ROOT hands over fist Funds holding $ROOT increased AGAIN QoQ from 176 funds to 199 funds a 13.07% increase. Total 13F share ownership increases 18.96% from 7.895M to 9.391M. 57 New positions were opened and 83 funds INCREASED their positions(a 151.52% increase QoQ) $ENPH $FSLR $BBAI $COEP

4 · Reply

Market Cap	49.09M
Revenue (ttm)	0.00
Net Income (ttm)	-10.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.02

Volume	133,600
Avg Vol	47,126
Day's Range	N/A - N/A
Shares Out	3.51M
Stochastic %K	88%
Beta	-0.59
Analysts	Strong Buy
Price Target	$3.00